Local Adverse Reactions Decreased Over Time During Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) Treatment in Patients with PID

被引：0

作者：

Stein, Mark ^{[1
]}

Wasserman, Richard L. ^{[2
]}

Melamed, Isaac ^{[3
]}

Gupta, Sudhir ^{[4
]}

Kobrynski, Lisa ^{[5
]}

Rubinstein, Arye ^{[6
,7
]}

Rabbat, Christopher J. ^{[8
]}

Engl, Werner ^{[9
]}

McCoy, Barbara ^{[10
]}

Leibl, Heinz ^{[9
]}

Yel, Leman ^{[10
]}

机构：

[1] Allergy Associates Palm Beaches, North Palm Beach, FL USA

[2] Allergy Partners North Texas Res, Dallas, TX USA

[3] IMMUNOe Hlth Ctr, Centennial, CO USA

[4] Univ Calif Irvine, Irvine, CA USA

[5] Emory Univ, Atlanta, GA 30322 USA

[6] Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Montefiore Hosp, Bronx, NY USA

[8] Shire, Chicago, IL USA

[9] Shire, Vienna, Austria

[10] Shire, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2017年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

PO - 136

引用

页码：S54 / S54

页数：1

共 43 条

[31] LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID)
Wasserman, Richard L.
Melamed, Isaac
Stein, Mark
Kobrynski, Lisa
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 314 - 314
[32] Patient Preferences for Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHy) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
Ito, Diane
Ye, Xiaolan
Xiong, Yan
Li-McLeod, Josephine
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 376 - 376
[33] Modeled Economic Impact of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% with Recombinant Human Hyaluronidase (IGHy) or Intravenous Immunoglobulin (IGIV) in Primary Immunodeficiency (PI) Patients
Iyer, Ravi
Luo, Michelle
Li-McLeod, Josephine
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 397 - 397
[34] Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases
Speth, Fabian
Haas, Johannes-Peter
Hinze, Claas H.
PEDIATRIC RHEUMATOLOGY, 2016, 14
[35] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): PHASE 3 EXTENSION STUDY IN PRIMARY IMMUNODEFICIENCY DISEASE
Melamed, I.
Wasserman, R. L.
Stein, M.
Rubenstein, A.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 132 - 133
[36] Patient Preferences for Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHY) in Adults with Primary Immunodeficiencies (PI): Phase 3 Study Results
Ito, D.
Ye, X.
Xiong, Y.
Li-McLeod, J.
Schiff, R.
Faivre, P.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S381 - S382
[37] Long Term Safety, Efficacy, and Tolerability of Recombinant Human Hyaluronidase [RHUPH20] -Facilitated Subcutaneous Infusion of Immunoglobulin G (IGG) (HYQVIA; IGHY) in Adults with Primary Immunodeficiencies (PI)
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S310 - S311
[38] Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
Stein, Mark R.
Wasserman, Richard L.
Melamed, Isaac
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
McCoy, Barbara
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 380 - 381
[39] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNE GLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE: PHASE 3 EXTENSION STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES
Melamed, I.
Wasserman, R.
Stein, M. R.
Rubinstein, A.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D. M.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A98 - A99
[40] Safety and Pharmacokinetics (Pk) of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Extension Study of a Phase 3 Pivotal Trial
Melamed, Isaac
Wasserman, Richard L.
Stein, Mark R.
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 379 - 379

← 1 2 3 4 5 →